Giardiasis Stomach Bug Linked to Ongoing IBS and Chronic Fatigue, 3 Years Post Infection


Research published online in GUT has shown that infection with the intestinal parasite, Giardia lamblia, more than triples the risk of persistent irritable bowel syndrome and chronic fatigue, and can last up to three years.

Furthermore, the infection seems to spark an increased risk of having both conditions at the same time, prompting the authors to suggest that ‘the long term clinical consequences of Giardia may be more severe than previously thought.’

Giardia lamblia is a parasite that is a common source of acute and longer term gut infection, and frequently implicated in travellers’ diarrhoea in tropical and subtropical areas, particularly where hygiene is poor.

It is mainly spread through contaminated drinking water, but it can also be passed on through person to person contact. Previously it was believed that once treated, it did not cause any long term problems. However, this recent research carried out by Dr Knut-Arne Wensaas and colleagues in Norway suggests otherwise.

The researchers tracked the health of 817 local residents who had become infected with Giardia in 2004 and over 1000 healthy people, matched for age and sex, for a period of three years. The source of the infection was contaminated water from a reservoir in Bergen, Norway.

They found that the prevalence of irritable bowel syndrome (IBS) was significantly higher in those who had had the infection, with these individuals being more than 3 times as likely to have persistent IBS, after taking account of factors likely to unduly influence the results.

They were also 4 times as likely to have chronic fatigue symptoms.

In addition, it was found that the likelihood of having both conditions together was almost 7 times as high amongst those who had had the infection.

Normally, the prevalence of IBS and chronic fatigue tends to be higher in women, but there was no evidence of a gender bias among the study participants.

Giardia infection is not endemic in Norway, and the researchers caution that their findings may not be applicable to countries outside the developed world: further research would be needed before such conclusions could be drawn. The paper can be viewed in full here.

For more information about Prime Endoscopy Bristol please click here.